KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) Invested Capital (2016 - 2026)

Gsk has reported Invested Capital over the past 14 years, most recently at -$7.1 billion for Q1 2026.

  • For Q1 2026, Invested Capital rose 3.49% year-over-year to -$7.1 billion; the TTM value through Mar 2026 reached -$29.2 billion, up 3.87%, while the annual FY2025 figure was $71.4 billion, 10.28% up from the prior year.
  • Invested Capital for Q1 2026 was -$7.1 billion at Gsk, down from $71.4 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $71.4 billion in Q4 2025 and troughed at -$7.8 billion in Q3 2024.
  • A 5-year average of $6.5 billion and a median of -$7.0 billion in 2022 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: plummeted 30.69% in 2022 and later soared 83.66% in 2024.
  • Year by year, Invested Capital stood at $32.6 billion in 2022, then grew by 8.07% to $35.2 billion in 2023, then soared by 83.66% to $64.7 billion in 2024, then rose by 10.28% to $71.4 billion in 2025, then plummeted by 109.97% to -$7.1 billion in 2026.
  • Business Quant data shows Invested Capital for GSK at -$7.1 billion in Q1 2026, $71.4 billion in Q4 2025, and -$7.5 billion in Q3 2025.